Copied
 
 
Formål
Formål
Selskabets formål er at udvikle idèer og præparater til sygdomsbekæmpelse ad medicinsk vej, at producere og sælge sådanne præparater eller idèer, at eje aktier i selskaber med samme formål samt at udøve virksomhed, som står i naturlig forbindelse hermed.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 27.01.2015 (3380 dage).
Ingen historik.
Status
Virksomhedsstatus
NORMAL.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 21.09.2006 (6430 dage).
Ingen historik.
Branche
Branche
Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721900).
Sidst opdateret den 26.11.2014 og angivet som gældende fra 01.01.2014 (3771 dage).
HistorikStartStop
Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721900)01.01.2014
Fremstilling af farmaceutiske præparater (212000)01.09.200831.12.2013
Uoplyst (999999)01.01.200831.08.2008
Uoplyst (980000)21.09.200631.12.2007
Revision
Revisionfravalgt
false.
Sidst opdateret den 11.03.2015 og angivet som gældende fra 17.12.2007 (5978 dage).
Ingen historik.
Revisor
Revisor
DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB
Sidst opdateret den 09.02.2015 og angivet som gældende fra 13.10.2011 (4582 dage).
Form
Virksomhedsform
60.
Sidst opdateret den 17.12.2007 og angivet som gældende fra 11.12.2007 (5984 dage).
HistorikStartStop
6011.12.2007
8021.09.200610.12.2007
Kontakt
Ingen nuværende registrering.
Ingen historik.
Telefon
Telefonnummer
36944486.
Sidst opdateret den 26.09.2008 og angivet som gældende fra 01.09.2008 (5719 dage).
Ingen historik.
Navne
Tegningsregel
Tegningsregel
Selskabet tegnes af bestyrelsens formand i forening med en direktør eller af tre medlemmer af bestyrelsen.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 27.01.2015 (3380 dage).
Fortolkning (2 tegningsmuligheder)
formanden + 1 direktør
3 bestyrelsesmedlemmer
Ingen historik.
Ansatte
29.04.2024
Kapital
29.04.2024
Fra årsrapport
Type af revisorbistand:Auditor's report on audited financial statements
Navn på revisionsvirksomhed:Deloitte Statsautoriseret Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:33963556
Beskrivelse af revisor:State-Authorised Public Accountant
Virksomhedens regnskabsklasse:Reporting class C, large enterprise
Grundlag for konklusion (revision):Basis for opinionWe conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor’s responsibilities for the audit of the consolidated financial statements and the parent financial statements" section of this auditor’s report. We are independent of the Group in accordance with the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):OpinionWe have audited the consolidated financial statements and the parent financial statements of Ascendis Pharma A/S for the financial year January 1 - December 31, 2022 , which comprise the statements of profit or loss and other comprehensive income, statements of financial position, statements of changes in equity, cash flow statements and notes, including a summary of significant accounting policies, for the Group as well as the Parent. The consolidated financial statements are prepared in accordance with the International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”), and as adopted by the European Union (“EU”). The financial statements include additional disclosures for reporting class C large sized enterprises as required by the Danish Executive Order on Adoption of IFRS as issued in accordance with the Danish Financial Statements Act. In our opinion, the consolidated financial statements and the parent financial statements give a true and fair view of the Group’s and the Parent’s financial position at December 31, 2022 and of the results of its operations and cash flows for the financial year January 1 - December 31, 2022 in accordance with IFRS as adopted by the IASB and as adopted by the EU and additional requirements of the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on the management commentaryManagement is responsible for the management commentary. Our opinion on the consolidated financial statements and the parent financial statements døs not cover the management commentary, and we do not express any form of assurance conclusion thereon. In connection with our audit of the consolidated financial statements and the parent financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the consolidated financial statements and the parent financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the management commentary provides the information required under the Danish Financial Statements Act. Based on the work we have performed, we conclude that the management commentary is in accordance with the consolidated financial statements and the parent financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management commentary.
Bibranche
Bibranche
Udlejning af erhvervsejendomme.
Sidst opdateret den 15.02.2024 og angivet som gældende fra 01.11.2023 (180 dage).
Ingen historik.
Børsnoteret
29.04.2024
Ingen nuværende registrering.
Ingen historik.
Hjemmeside
29.04.2024
Ingen nuværende registrering.
Ingen historik.